TITLE

Long-term estrogen-plus-progestin increased venous thromboembolism and biliary tract surgery in postmenopausal women

PUB. DATE
January 2003
SOURCE
ACP Journal Club;Jan/Feb2003, Vol. 138 Issue 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on a study that investigated the role of long-term estrogen-plus-progestin in increasing the risk of venous throboembolism and biliary tract surgery in postmenopausal women. Assessment of the clinical characteristics of patients; Patient intervention; Outcome measures.
ACCESSION #
9083217

 

Related Articles

  • The French ESTHER Study of VTE. Speroff, Leon // OB/GYN Clinical Alert;May2007, Vol. 24 Issue 1, p6 

    The EStrogen and THromboEmbolism Risk (ESTHER) study is a case-control study performed with cases from 8 French hospitals and controls from the general population. The results were as follows: The authors concluded that transdermal estrogen is not associated with an increased risk of VTE, and...

  • Oral Contraceptives and Venous Thromboembolism: Which Are the Safest Preparations Available? Girolami, A.; Spiezia, L.; Rossi, F.; Zanon, E. // Clinical & Applied Thrombosis/Hemostasis;Apr2002, Vol. 8 Issue 2, p157 

    Oral contraceptive therapy is associated with a fourfold increased risk of venous thromboembolism as compared with age-matched non-users. The composition of oral contraceptives has varied considerably during the past two to three decades. The estrogen content (ethinylestradiol) has decreased and...

  • Menopausal Hormone Therapy and the Risk for VTE, AD. Elliott, William T. // Infectious Disease Alert;Dec2012 Pharmacology Watch, p1 

    The article discusses a research study on the risk of venous thromboembolism (VTE) in menopausal hormone therapy (HT) formulations. The study found higher risk of VTE in higher estrogen-progesterone combination therapy compared to estrogen-only formulation. It also notes findings of another...

  • Benefits and Risks of OCPs Beyond Contraception. Zepf, Bill // American Family Physician;5/1/2004, Vol. 69 Issue 9, p2233 

    Focuses on the benefits and risks of oral contraceptive pills (OCP). Guidelines on the use of estrogen-progestin oral contraceptives for women; Association of high estrogen doses with myocardial infarction and ischemic stroke; Risk of venous thromboembolism in patients taking pills with progestins.

  • Conjugated estrogen use increases VT risk.  // Reactions Weekly;5/6/2006, Issue 1100, p3 

    Discusses the results of a study regarding conjugated estrogen use in postmenopausal women without a uterus conducted by the Women's Health Initiative (WHI). Final adjudicated venous thromboembolism (VT) data from the WHI conjugated equine estrogen (CEE) trial of women aged 50 to 79 years who...

  • Progestogens and VTE risk when flying. Power, Jo // Pulse;7/8/2002, Vol. 62 Issue 27, p56 

    Gives advice on whether it is reasonable to offer progestogens to postpone menstruations for someone traveling abroad on a holiday. Association between long-haul air travel and risk of venous thromboembolism (VTE); Correlation between combined oral contraceptive intake and the risk of VTE.

  • NIH Findings: Controversy of Hormone Replacement Therapy. Sztykowski, Tadeusz; Burke, Robert E. // American Acupuncturist;Fall2002, Vol. 28, p16 

    Focuses on the controversy behind the use of combined estrogen and progestin in healthy menopausal women. Examination of the effect of Prempro on the prevention of heart disease; Association of the effects with the risk of breast and colon cancer; Decrease of libido among the menopausal women.

  • Study confirms value of progestin-estrogen combination.  // Mayo Clinic Health Letter;May1996, Vol. 14 Issue 5, p4 

    Presents information from a study on the value of progestin and estrogen. Progestin taken with estrogen offsets the risk of uterine cancer; Uses of estrogen; What progestin is.

  • Estrogen plus progestin increased coronary heart disease and breast cancer events in postmenopausal women. Lowe, Julia // ACP Journal Club;Sep/Oct2002, Vol. 137 Issue 2, p41 

    Presents information on a study that investigated the risks and benefits of estrogen plus progestin in healthy postmenopausal women. Design of the study; Analysis of the incidence of diseases between the placebo-controlled trial versus estrogen plus progestin; Rate of unfavorable and favorable...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics